Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

All GLG News Analyses Filed Under: Ophthalmology

Articles with lock require a GLG News subscription

Posted May 18, 2007

Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting
Analysis of: Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting | www.pipelinereview.com
Author: GLG Member Program Contributor

VEGF Trap could be better than Lucentis or Avastin in that it can neutralize VEGF isoforms that Lucentis or Avastin cannot neutralize.

Posted May 18, 2007

Fish and Vitamin D Linked to Lower Risk of Macular Degeneration
Analysis of: Fish and Vitamin D Linked to Lower Risk of Macular Degeneration | www.medpagetoday.com
Author: GLG Member Program Contributor

This dietary case control study showed that higher dietary levels of omega-3 fatty acids, mainly from fatty fish, reduced the risk of age-related macular degeneration by 39%. This is very exciting and supports previous obersvational studies showing the protective effects of diet heavy in fish...

Posted May 18, 2007

Ranibizumab, PDT combination successfully treats neovascular AMD
Analysis of: Ranibizumab, PDT combination successfully treats neovascular AMD | www.osnsupersite.com
Author: GLG Member Program Contributor

Ranibizumab and PDT are both approved treatments and hence are interesting to see how they compare in combination.

Posted May 17, 2007

This article is important in that although we presently have ocular vitamins implicated in the the retardation of AMD they do not currently include omega 3 fatty acids or Vitamin D. At this point the only treatments available for dry AMD is based on the first ARED study- which implicated...

Posted May 15, 2007

This study from Italy shows that PDT combined with monthly Lucentis is much more beneficial compared to PDT alone. Does this data show a role for PDT in the current anti-Vegf era and allow Novartis to still a claim share in this market?

Posted May 14, 2007

The treatment of "wet" Age-related macular degeneration is a billion dollar market. There has been much excitement regarding the management of of "wet" AMD centered on inhibiting vascular endothelial growth factor (VEGF). Over the past three years, there have been many inhibitors of VEGF...

Posted May 14, 2007

Possible Seasonal Link to Uveitis
Analysis of: Possible Seasonal Link to Uveitis | www.medscape.com
Author: GLG Member Program Contributor

This study reports that uveitis cases peak in the spring time alleging a link a between springtime allergies and uveitic flare up and episodes. If allergies indeed play a role, it may suggest a common mechanism on uveitic episodes and spur novel treatment modalities to manage uveitis in the future....

Posted May 14, 2007

Ranibizumab effective for macular edema due to retinal vein occlusions, ophthalmologist says
Analysis of: Ranibizumab effective for macular edema due to retinal vein occlusions, ophthalmologist says | www.osnsupersite.com
Author: GLG Member Program Contributor

There are not many effective treatment options for macular edema secondary to retinal vein occlusions. This pilot study shows that Lucentis can be effective to improve vision and decrease swelling in retinal vein occlusions; and could be another indication for Lucentis.

Posted May 2, 2007

Novagali Pharma Announces FDA Clearance of IND for US Pivotal Phase III Trial of Nova22007 for Treatment of Dry Eye Syndrome
Analysis of: Novagali Pharma Announces FDA Clearance of IND for US Pivotal Phase III Trial of Nova22007 for Treatment of Dry Eye Syndrome | www.pipelinereview.com
Author: GLG Member Program Contributor

The current paradigm of Dry Eye disease revolves around inflammation as a key and essential component in its development and progression. Many current and developing regimens (artificial tears, secretagogues such as Ecabet sodium and diquafosol and 15-HETE, mucomimetics such as Milicin, etc...) do...

Posted April 25, 2007

FDA Approves Fast Track Designation for Naryx Pharma’s Product for Chronic Sinusitis
Analysis of: FDA Approves Fast Track Designation for Naryx Pharma’s Product for Chronic Sinusitis | www.naryxpharma.com
Author: GLG Member Program Contributor

Too early to call this a potential blockbuster. But keep an eye on it.

Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Next131 to 140 of 212

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-06T21:45:17.077

All GLG News Analyses Filed Under: Ophthalmology

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare